I had the DNX-2401 injected in November and have been receiving Infusions of Keytruda every three weeks as part of their most recent trial. So far everything seems to be working with no new symptoms and reductions in some symptoms (visual anomalies) but my field deficit increased.
But the MRI's since have not been conclusive regarding effectiveness. The Contrast area continues to increase but at a very very slow rate <.5mm every 4 weeks. I was setup for a debulking last week but the MRI before surgery showed stability so everything has been postponed for a month.
Glad to hear you're not having any major side effects. This is one of my favorite trials. The following paper just came out and might be relevant to your case.
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4131-1 Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.
It remains indeed very difficult to distinguish relapse from immune reaction. I follow the iRANO criteria published by Okada in 2015 for assessment. One can also do a PET investigation, as we published in J Neurosurgery in 2004. Also angio-MRI might be of help, as we published in Neuroradiology in 2011.
I had the DNX-2401 injected in November and have been receiving Infusions of Keytruda every three weeks as part of their most recent trial. So far everything seems to be working with no new symptoms and reductions in some symptoms (visual anomalies) but my field deficit increased.
ReplyDeleteBut the MRI's since have not been conclusive regarding effectiveness. The Contrast area continues to increase but at a very very slow rate <.5mm every 4 weeks. I was setup for a debulking last week but the MRI before surgery showed stability so everything has been postponed for a month.
Marc
Glad to hear you're not having any major side effects. This is one of my favorite trials. The following paper just came out and might be relevant to your case.
Deletehttps://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4131-1
Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.
It remains indeed very difficult to distinguish relapse from immune reaction. I follow the iRANO criteria published by Okada in 2015 for assessment. One can also do a PET investigation, as we published in J Neurosurgery in 2004. Also angio-MRI might be of help, as we published in Neuroradiology in 2011.
DeleteUCLA is also looking at PH balance readings from MRI's. I am going to do a research Trial MRI for them in a couple of weeks.
ReplyDeleteMarc